VYCO VYCOR MEDICAL INC

VYCO financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1424768 Exchange: OTC SIC: 3841 (Surgical & Medical Instruments & Apparatus) Latest filing: 10-Q filed Nov 13, 2026 Data checked: Nov 16, 2026
Showing 3 of 16 annual and 0 of 64 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$1.71M (Jun 2025)
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Incorporated
DE
Fiscal Year End
December (1231)
Phone
562.558.2000
EIN
203369218
Headquarters
BOCA RATON,, FL, 33487
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$1.71M
Net Income
$-64.13K
Total Assets
$964.88K
Total Equity
$-4.41M
Total Debt
-
Free Cash Flow
-
Ratios
Gross Margin
82.4%
Operating Margin
2.5%
Net Margin
-3.8%
Return on Equity
1.5%
Return on Assets
-6.6%
Current Ratio
0.13x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, VYCOR MEDICAL INC recorded $1.86M of revenue, net loss of $72.43K, and an operating cash outflow of $13.47K. Revenue of $1.86M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $1.59M in fiscal 2024, revenue recorded a 17.2% year-over-year increase. Diluted earnings per share were -$0.01, translating the period’s attributable earnings into the amount reported for each diluted share. Diluted shares averaged 33.37M; this is the reported share base over which the company’s diluted per-share earnings were spread. Total assets stood at $830.42K, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 2.24x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $1.56M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross margin was 83.8%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was $33.90K, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 1.8%, showing how efficiently sales converted into operating profit. The company ended the period with a net loss of $72.43K, extending the operating result through all remaining items. Net margin was -3.9%, reflecting a loss equal to 3.9% of reported revenue. Reported EBITDA totaled $93.42K, adding a pre-interest, tax, depreciation, and amortization perspective to the profitability profile. The pretax result was a loss of $70.19K, establishing the deficit before tax effects. Pretax margin was -3.8%, reflecting a pre-tax loss equal to 3.8% of revenue. Relative to total assets, the net loss represented 8.7%. Compared with a $107.20K net loss in fiscal 2024, the current loss improved to $72.43K.

Liquidity and Capital Structure

At period end, the $830.42K asset base was financed through $4.92M of liabilities and -$4.09M of equity. The company reported negative equity of -$4.09M, a capital deficit that reduces its ability to absorb losses through book equity. At period end, current assets of $563.42K compared with current liabilities of $4.78M, defining the company’s short-term resource position. Current assets covered only 0.12x of current liabilities, so current liabilities exceeded current assets at period end. Cash and equivalents totaled $86.98K, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 1.8%, excluding receivables and other current assets. Book equity represented -492.1% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 592.1%, placing reported obligations against the full positive asset balance. The cash-to-assets relationship was 10.5%, comparing reported cash and equivalents with the full positive asset balance. Total assets were 16.8% lower than fiscal 2024 assets of $998.12K, measuring the company’s own balance-sheet change. The reported cash balance changed 17.7% from $105.65K in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $13.47K, rather than cash generation from operations. Capital expenditures used $5.22K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Operating cash flow and capital spending combined to leave a $18.70K cash deficit after capital spending. Relative to revenue, the post-investment cash deficit represented 1.0%. The cash deficit after capital spending represented 2.3% of the period-end asset base. Operating cash flow moved from a $60.11K inflow in fiscal 2024 to a $13.47K outflow.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for VYCOR MEDICAL INC
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $1.86M $1.59M $1.46M
Cost of Revenue $302.29K $166.81K $144.95K
Gross Profit $1.56M $1.42M $1.32M
OPERATING EXPENSES
R&D Expense $9.96K $15.33K $22.56K
SG&A Expense $1.46M $1.36M $1.20M
Other Operating Expenses (derived) $59.52K $59.52K $57.50K
Operating Income $33.90K $-9.15K $40.19K
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $-104.09K $-97.81K $-103.27K
Pretax Income $-70.19K $-106.95K $-63.08K
Net Income $-72.43K $-107.20K $-69.69K
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.01 $-0.01 $-0.01
Diluted Shares 33.37M 32.88M 32.60M
EBITDA $93.42K $50.38K $97.69K
Depreciation & Amortization $59.52K $59.52K $57.50K
Balance Sheet
ASSETS
Cash & Equivalents $86.98K $105.65K $57.29K
Accounts Receivable $218.89K $245.26K $215.23K
Inventory $159.20K $146.08K $234.15K
Other Current Assets $97.23K $121.71K $76.68K
Current Assets $563.42K $619.61K $584.09K
PP&E (Net) $133.94K $192.69K $252.40K
Other Noncurrent Assets $133.06K $185.81K $155.80K
Noncurrent Assets $267.00K $378.50K $408.21K
Total Assets $830.42K $998.12K $992.30K
LIABILITIES
Accounts Payable $84.76K $147.57K $117.80K
Current Liabilities $4.78M $4.50M $4.07M
Other Noncurrent Liabilities - - $2.96M
Noncurrent Liabilities $135.83K $191.66K $243.29K
Total Liabilities $4.92M $4.69M $4.32M
EQUITY
Common Stock $3.35K $3.35K $3.27K
Additional Paid-in Capital $29.43M $29.43M $29.37M
Retained Earnings $-33.65M $-33.25M $-32.82M
Accumulated OCI $127.68K $127.68K $127.68K
Total Equity $-4.09M $-3.69M $-3.33M
Total Liabilities & Equity $830.42K $998.12K $992.30K
SUPPLEMENTAL
Shares Outstanding 33.37M 33.37M 32.63M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-13.47K $60.11K $29.43K
Capital Expenditures $5.22K $5.37K $9.39K
Cash from Investing $-4.38K $-4.20K $-9.39K
Cash from Financing $-812 $-7.55K $211
Free Cash Flow $-18.70K $54.74K $20.04K
Beginning Cash (CFS) $105.65K $57.29K $37.04K
Net Change in Cash $-18.67K $48.36K $20.26K
Effect of FX on Cash $0 $0 $1
Calculated Ending Cash $86.98K $105.65K $57.29K
Cash per BS $86.98K $105.65K $57.29K
Cash scope difference (CFS − BS) - - -
Cash per CFS $86.98K $105.65K $57.29K

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is VYCOR MEDICAL INC's annual revenue?

VYCOR MEDICAL INC reported $1.71M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is VYCOR MEDICAL INC profitable?

No. VYCOR MEDICAL INC reported $-64.13K in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.